Table 3 Comparison of clinical and laboratory characteristics between three groups according functional disability and disease activity.

From: Functional disability is related to serum chemerin levels in rheumatoid arthritis

Variables

Disability + high DAS28-ESR (n = 24)

Disability + low DAS28-ESR (n = 19)

Non-disabled (n = 39)

p

Age (years)

56Ā (35–73)

55 (37–77)

59 (30–79)

0.90

Body mass index

28 (19–35)

28 (22–34)

26 (19–46)

0.10

Disease duration (years)

14 (0.1–27)

8 (1–30)

9 (0.1–30)

0.39

RF (IU/mL)

57 (8–765)

67 (9–641)

20 (5–118)

0.18

ESR (mm/h)

33.5 (5–354)

24 (7–45)

21 (0.1–43)

0.06

Adipokines

Chemerin, (ng/mL)

160 (77–1402)

136 (71–235)

112 (56–277)

0.008

Leptin, (ng/mL)

31 (3–115)

25 (4–175)

33 (7–99)

0.98

Adiponectin, (ng/mL)

7767 (1328–25,529)

12,886 (3921–17,166)

8927 (1368–24,532)

0.33

Resistin, (pg/mL)

7 (2–13)

7 (4–10)

6 (4–20)

0.29

Visfatin, (ng/mL)

19 (2–172)

21 (6–255)

20 (2–278)

0.87

Cytokines

IL-6, (pg/mL)

7 (1–110)

6 (1–32)

4 (0.4–29)

0.10

TNF-α , (pg/mL)

6 (1–474)

6 (3–714)

5 (0.3–668)

0.18

IL-1β, (pg/mL)

7 (5–11)

7 (1–9)

7 (5–15)

0.87

IL-18, (pg/mL)

389 (137–1027)

333 (141–672)

388 (127–1767)

0.60

Adhesion cell molecule

E-Selectin, (pg/mL)

48 (32–84)

39 (9–84)

40 (13–84)

0.12

Treatment

Methotrexate, n (%)

11 (46)

9 (47)

26 (67)

0.22

Sulfasalazine, n (%)

9 (38)

11 (58)

17 (44)

0.30

Chloroquine, n (%)

6 (25)

3 (16)

11 (28)

0.64

Azathioprine, n (%)

4 (17)

3 (16)

3 (8)

0.47

b-DMARDs, n (%)

6 (25)

3 (16)

4 (10)

0.13

Corticosteroid, n (%)

21 (88)

18 (95)

19 (49)

0.008

Prednisone doses, mg/day

5 (2.5–10)

5(2.5–7.5)

5 (2.5–10)

0.30

  1. RF rheumatoid factor, ESR erythrocyte sedimentation rate, IL-6 interleukin-6, TNF-α tumor necrosis factor α, IL-1β interleukin-Beta 1, IL-18 interleukin-18.
  2. Three groups: (a) rheumatoid arthritis with functional disability and higher disease activity (disability: HAQ-Di, score ≄ 0.6 + high DAS28-ESR, score > 3.2); (b) rheumatoid arthritis with functional disability and lower disease activity (disability: HAQ-Di, score ≄ 0.6 + low DAS28-ESR, score ≤ 3.2) and (c) rheumatoid arthritis patients without functional disability (non-disabled). Qualitative variables are expressed in frequency (%); quantitative variables are expressed in median (ranges). Proportions were compared with chi square test and the comparison of quantitative variablesĀ wasĀ performed with Kruskal–Wallis test.